Details:
Under the partnership, Boehringer Ingelheim will contribute an experimental agent to CONQUEST, a highly innovative clinical trial platform created by the SRF to efficiently advance promising treatments for scleroderma.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Scleroderma Research Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 03, 2023
Details:
Company is currently evaluating the safety and efficacy of Felzartamab with anti-PLA2R antibody-positive membranous nephropathy and IG-A Nephropathy. Felzartamab is a human monoclonal HuCAL anti-CD38 antibody for the treatment of autoimmune diseases and multiple myeloma.
Lead Product(s): Felzartamab
Therapeutic Area: Immunology Product Name: MOR202
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2021
Details:
The acquisition of the royalties will enable Immunic to realize the full market potential of IMU-838, not only as a treatment for RRMS but also as a potential new therapeutic option for ulcerative colitis, Crohn’s disease, COVID-19, and primary sclerosing cholangitis.
Lead Product(s): Vidofludimus calcium anhydrous
Therapeutic Area: Immunology Product Name: IMU-838
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Immunic Therapeutics
Deal Size: $17.2 million Upfront Cash: Undisclosed
Deal Type: Agreement March 31, 2021